Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Antisense Therapeutics Limited ATHJF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • AU • USD

SharesGrow Score
37/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Antisense Therapeutics Limited (ATHJF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.01. It has a SharesGrow Score of 35/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $3M, +94.8%/yr average growth. Net income is $12M (loss), growing at -24.2%/yr. Net profit margin is -401.6% (negative). Gross margin is 97.9% (+15.8 pp trend).

Balance sheet: total debt is $39,874 against $9M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.81 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $15M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

ATHJF SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ATHJF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
ATHJF: +94.8%/yr revenue is, -24.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ATHJF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.81 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
ATHJF: Gross margin is 97.9% (+15.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
ATHJF: Net profit margin is -401.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.01-0.075
Volume2.5K
Market Cap$19.64M
Beta (1Y)0.87
Share Statistics
EPS (TTM)-0.01
Shares Outstanding$881.21M
IPO Date2009-09-08
CEOJames Garner MBA
Financial Highlights & Ratios
Revenue (TTM)$2.97M
Gross Profit$2.91M
EBITDA$-11.9M
Net Income$-11.92M
Operating Income$-11.83M
Total Cash$11.87M
Total Debt$39.87K
Net Debt$-11.83M
Total Assets$14.53M
Price / Earnings (P/E)-0.9
Price / Sales (P/S)6.62
Analyst Forecast
Company Info
CountryAU
ExchangeOther OTC
CurrencyUSD
ISINAU0000317281

Price Chart

Track all markets on TradingView
ATHJF
Antisense Therapeutics Limited ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.01 52WK RANGE 0.08

People Also View

APNHF
APNHF
Aspen Pharmacare Holdings Limited
$8.69
+5.98%
 AVCNF
AVCNF
Avicanna Inc.
$0.11
-2.06%
 CRRTF
CRRTF
Crescita Therapeutics Inc.
$0.54
+0.00%
 ABTI
ABTI
Alterola Biotech, Inc.
$0.01
+0.00%
 BCBCF
BCBCF
The BC Bud Corporation
$0.04
-3.31%
 ANTCF
ANTCF
Aion Therapeutic Inc.
$0.00
+0.00%
 ACNNF
ACNNF
AusCann Group Holdings Ltd
$0.00
-15.56%
 BINP
BINP
Bionoid Pharma Inc.
$0.03
0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message